Higher doses are not associated with better outcomes in available studies and may increase the chance of injection-site reactions
Laekna Therapeutics is currently the most extensively invested biopharmaceutical company in the ActRII target space
In another study on a CSV model, the combination of dihydrocaffeic acid (DHCA) and Malvidin-3-O-glucoside (Mal-gluc) was observed to have a corrective effect on CSV-induced expression and selective splicing of neurexins [76]
On the one hand, medication offers patients a lower upfront cost, but if it is not covered by insurance, it can require between $800 and $1,000 in investment each month
In the central nervous system (CNS), it is abundant in the hypothalamus and brainstem nuclei, including the arcuate nucleus and area postrema [1315]
The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery